Filing Flows › Novo Nordisk A S (NVO) › R&D spending
Novo Nordisk A S (NVO) R&D spending by quarter
Novo Nordisk A S' R&D spending was $19.9B in Q3 2026 (third quarter 2026), +12% from Q2 2026. Over the last 6 quarters it ranged from $10.3B (Q1 2026) to $19.9B (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $19.9B | +12% | +29% |
| Q2 2026 | $17.8B | +73% | +52% |
| Q1 2026 | $10.3B | -30% | — |
| Q4 2025 | $14.6B | -5% | — |
| Q3 2025 | $15.4B | +32% | — |
| Q2 2025 | $11.7B | — | — |
Q3 2026 at a glance
Novo Nordisk A S, Q3 2026: revenue $79.2B (+6% year over year), operating margin 29.1%, net earnings $16.7B, operating cash flow $41.7B. The chart follows the revenue to costs, profit and cash.
Questions
What is Novo Nordisk A S' R&D spending?
Novo Nordisk A S' R&D spending was $19.9B in Q3 2026 (third quarter 2026), +12% from Q2 2026.
How has Novo Nordisk A S' R&D spending changed?
Over the last 6 quarters it ranged from $10.3B (Q1 2026) to $19.9B (Q3 2026).